Ebos Group (EBO) Fundamentals 2026 — P/E 17.8x, Revenue Analysis | SniperIQ
Ebos Group (EBO) is a AU-listed Healthcare company in Medical - Distribution with a market capitalization of A
Ebos Group (EBO) has a market capitalization of approximately A
Ebos Group's trailing twelve-month P/E ratio is 17.8x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Ebos Group runs a net profit margin of 1.4%, a gross margin of 10.3%, and an operating margin of 2.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Ebos Group reported revenue of NZD 13.2B for fiscal year 2025, with net income of NZD 232M and earnings per share (EPS) of 1.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Ebos Group offers a trailing dividend yield of about 5.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Ebos Group carries a debt-to-equity ratio of 0.82x and a current ratio of 1.24x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ebos Group (EBO) the key facts are: market cap A
Get Ebos Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.